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Cancer vaccines based on tumor-associated antigens are
rarely curative in advanced cancer. This limitation relates
to the heterogeneity of cancer due to defects in antigen
presentation and altered immunophenotypes. Therefore,
another method to promote anti-tumor immunity is to
prime T cells against tumor-associated stromal cells. We
have reported [1] that IL-12 gene therapy of established
HLA-A2neg B16 melanomas in HLA-A2+ transgenic mice
resulted in CD8+ T cell-mediated immunity against the
host HLA-A2+ stromal cells within the tumor microenvir-
onment (TME). We have also shown [2] that vaccines
based on a subset of tumor blood vessel antigen (TBVA)-
derived peptides (DLK1, EphA2, HBB, NRP1, PDGFRÎ²,
RGS5 or TEM1) prevented HLA-A2neg MC38 tumor
establishment and promoted the regression of tumors in
HLA-A2+ mice by CD8+ T cell targeting of HLA-A2+
pericytes and vascular endothelial cells in the TME. Based
on this pre-clinical data, we propose to undertake a Susan
G. Komen -funded (IIR13261822) clinical trial of chemo-
immunotherapy using the immunomodulatory drug gem-
citabine with a dendritic cell vaccine pulsed with six HLA-
A2-presented TBVA-derived peptides (DLK1310-318,
EphA2883-891, HBB31-39, NRP1433-441, RGS55-13 and
TEM1691-700) in 30 HLA-A2+ patients with metastatic
breast cancer. The specific aims of this study are to deter-
mine vaccine-induced generation of TBVA-Tc1 immunity
and clinical response.
Authors’ details
1Seidman Cancer Center, Cleveland, Ohio, USA. 2University of Pittsburgh
Cancer Institute, Pittsburgh, Pennsylvania, USA. 3Taussig Cancer Center,
Cleveland, Ohio, USA.
Published: 14 August 2015
References
1. Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB,
Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM,
Storkus WJ: Intratumoral IL-12 gene therapy results in the crosspriming
of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther.
2011, 19(4):805-14.
2. Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y,
Mukhopadhyay D, Cohen PA, Storkus WJ: Vaccines targeting tumor blood
vessel antigens promote CD8(+) T cell-dependent tumor eradication or
dormancy in HLA-A2 transgenic mice. J Immunol 2012, 188:1782-8.
doi:10.1186/2051-1426-3-S1-P3
Cite this article as: Baar et al.: Pilot trial of a type I - polarized
autologous dendritic cell vaccine incorporating tumor blood vessel
antigen-derived peptides in patients with metastatic breast cancer.
Journal for ImmunoTherapy of Cancer 2015 3(Suppl 1):P3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1Seidman Cancer Center, Cleveland, Ohio, USA
Full list of author information is available at the end of the article
Baar et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 1):P3
http://www.immunotherapyofcancer.org/content/3/S1/P3
© 2015 Baar et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
